Cargando…
The argument against the use of dupilumab in patients with limited polyp burden in chronic rhinosinusitis with nasal polyposis (CRSwNP)
Dupilumab and other biologics have revolutionized the management of recalcitrant polyps in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP). Despite strong evidence for the efficacy of dupilumab in treating polyps, factors such as cost and uncertain efficacy over surgery have limit...
Autores principales: | Hardison, Scott A., Senior, Brent A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537999/ https://www.ncbi.nlm.nih.gov/pubmed/37759322 http://dx.doi.org/10.1186/s40463-023-00668-z |
Ejemplares similares
-
WITHDRAWN: Dupilumab: A review of potential in the
treatment of Chronic rhinosinusitis with nasal polyps (CRSwNP)
por: Sree Sudha, T.Y., et al.
Publicado: (2020) -
Cost–Utility Analysis of Dupilumab for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Italy
por: De Corso, Eugenio, et al.
Publicado: (2022) -
Olfaction Recovery following Dupilumab Is Independent of Nasal Polyp Reduction in CRSwNP
por: Cantone, Elena, et al.
Publicado: (2022) -
Guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (CRSwNP) in Brazil
por: Anselmo-Lima, Wilma T., et al.
Publicado: (2021) -
Computational fluid dynamic modeling of the effect of dupilumab in the management of anosmia secondary to chronic rhinosinusitis with nasal polyps (CRSwNP)
por: Lepley, Thomas J., et al.
Publicado: (2022)